key: cord-0940645-npo30b4a authors: Peron, Angela; La Briola, Francesca; Bruschi, Fabio; Terraneo, Silvia; Vannicola, Chiara; Previtali, Roberto; Perazzoli, Sabrina; Morenghi, Emanuela; Bulfamante, Gaetano; Vignoli, Aglaia; Canevini, Maria Paola title: Tuberous sclerosis complex (TSC), lymphangioleiomyomatosis, and COVID‐19: The experience of a TSC clinic in Italy date: 2020-08-17 journal: Am J Med Genet A DOI: 10.1002/ajmg.a.61810 sha: 0dfd22f01002aa95e09da50a6ffee0ffa5186dcc doc_id: 940645 cord_uid: npo30b4a Individuals with comorbidities are at higher risk of coronavirus disease 2019 (COVID‐19) and worse outcome, but little information has been available about patients with genetic diseases and COVID‐19. This study aims at evaluating the presence and outcome of COVID‐19 in a cohort of Italian patients with tuberous sclerosis complex (TSC) and/or lymphangioleiomyomatosis (LAM), and at reviewing the possible effects of mTOR inhibitors on SARS‐CoV‐2 infection. We included 102 unselected individuals with a diagnosis of TSC and/or LAM assessed between January 1, 2020 and April 24, 2020 (29% children, 71% adults). Twenty‐six patients were on mTOR inhibitors. Demographic data, TSC manifestations, presence, and outcomes in individuals with confirmed or suspected SARS‐CoV‐2 infection were evaluated. Health status and outcomes of all patients on mTOR inhibitors were assessed. One patient with severe TSC had polymerase chain reaction (PCR)‐confirmed SARS‐CoV‐2 infection, was admitted to ICU, and died. Nine additional patients either met the definition of suspect case or presented with at least two of the most common symptoms of SARS‐CoV‐2 infection. All recovered fully. None of the patients treated with mTOR inhibitors for their underlying comorbidities was diagnosed with COVID‐19, and those who showed suspicious respiratory symptoms recovered fully. This cohort study provides preliminary information on COVID‐19 in people with TSC in Italy and suggests feasibility to systematically evaluate the role of mTOR inhibitors in SARS‐CoV‐2 infection. Coronavirus disease 2019 (COVID-19) has so far affected over 5 million people worldwide, and the Lombardy region in Italy was one of the first and most impacted areas after Wuhan, China (Zehender et al., 2020) . Individuals with comorbidities are at higher risk of infection and worse outcome (Wu et al., 2020) , but little information has been available about patients with rare genetic diseases and COVID-19. Tuberous sclerosis complex (TSC) is one of the most common rare diseases, affecting 1 in 6,000 live births and causing multisystem morbidities in the brain, kidneys, heart, eyes, and skin (Northrup & Krueger, 2013) . Adult women may have cystic pulmonary involvement (lymphangioleiomyomatosis [LAM] ) that could lead to respiratory insufficiency (Northrup & Krueger, 2013) . A sporadic form is also described in previously healthy women (S-LAM; Northrup & Krueger, 2013) . The only approved treatment is the use of mTOR inhibitors (Everolimus and Sirolimus), originally identified as immunosuppressants (Franz & Krueger, 2018) . Recommendations for patients with TSC during the pandemic are currently based on expert opinions (Tuberous Sclerosis Alliance, 2020; https://www.tsalliance.org/wp-content/uploads/ 2020/03/COVID-19-Considerations-for-TSC-Medical-Professionals-WEB.pdf). To provide evidence for these recommendations, we performed a study to investigate the presence and outcomes of SARS-CoV-2 infection in a cohort of Italian TSC patients. This retrospective cohort study was conducted at the multidisciplinary TSC Clinic of San Paolo University Hospital in Milan and was approved by the Institution's Ethics Committee. The institution is currently operating as a COVID hospital, with an ICU and six COVID wards, and the remaining COVID-free wards ensuring essential services. Our TSC clinic is the largest in Italy, comprises a dedicated LAM clinic, and offers diagnosis and care to 388 affected children and adults from various parts of the country (Peron et al., 2018) . We included in the study all individuals affected with TSC and/or LAM who were seen in the outpatient clinics between January 1, 2020 and April 24, 2020 (corresponding to the surge of the epidemiological curve in Italy) during regular visits before the lockdown and for essential in-person clinical encounters thereafter. We included also the patients assessed through phone visits after the lockdown. Although the first confirmed community spread of COVID-19 in Italy was identified on February 21, we decided to extend the assessment period back to January as there is evidence that SARS-CoV-2 was present in the country since then (Zehender et al., 2020) . We reviewed all medical records to identify confirmed SARS-CoV-2 infections and/or suspect cases as defined by the European Center for Disease Prevention and Control (2020) A total of 102 individuals with TSC and/or LAM were included. Demographic characteristics are summarized in Table 1 and treatment with mTOR inhibitors in Table 2 . Prevalence of TSC-related manifestations and molecular diagnosis were in line with those of the literature (Northrup & Krueger, 2013) , and phenotypes were of variable severity (Peron et al., 2018) , ensuring this is a representative sample of the general TSC population. Italian patients who were living abroad at the time of the interview or were out of the country during the pandemic and could not go back to Italy. c Assumed not to be tested, as only symptomatic individuals presenting to the emergency department or requiring hospitalization received nasopharyngeal swab in Italy as per government recommendations. All patients/caregivers reported they were strictly abiding to national recommendations, namely lockdown. Those allowed to go for a walk because of underlying comorbidities such as intellectual disability and autism spectrum disorder were practicing social distancing when outside their homes. Twenty-four of 26 patients who were on mTOR inhibitors continued treatment (those who discontinued treatment are displayed in Table 3 ). Complete information was available for all 102 patients until the end of February, and for 99/102 patients until the end of collection. (Keating et al., 2013) , and the use of low-dose Everolimus was found to decrease the infection rate in elderly volunteers enrolled in a randomized, double-blinded, placebo-controlled trial (Mannick et al., 2018) . In mice studies, Keating et al. (2013) The data that support the findings of this study are available in Supplementary Table SI . https://orcid.org/0000-0002-1769-6548 Aglaia Vignoli https://orcid.org/0000-0003-4638-4663 Case definition and European surveillance for COVID-19 mTOR inhibitor therapy as a disease modifying therapy for tuberous sclerosis complex Aggiornamento nazionale 28 aprile 2020 -ore 16:00 The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus mTOR regulation of lymphoid cells in immunity to pathogens Antiviral potential of ERK/-MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis TORC1 inhibition enhances immune function and reduces infections in the elderly News releases & International Tuberous Sclerosis Complex Consensus Group COVID-19 and rare diseases Deep phenotyping of patients with tuberous sclerosis complex and no mutation identified in TSC1 and TSC2 COVID-19 considerations for TSC medical professionals Coronavirus overview. Retrieved from www.who.int/health-topics/coronavirus#tab=tab_3 Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2 Genomic characterization and phylogenetic analysis of SARS-COV-2 in Italy The authors would like to thank all the colleagues of the TSC Clinic of the San Paolo University Hospital in Milan, especially Dr Rosangela Arancio, and the families for kindly participating in this study. Angela This column indicates the geographical residence and whether the patient was living in a group setting or at home.